Early Access — free while we kick the tires
EdgarHawk

Levy Adam Scott

CFO and Secretary

Officer
2 filings analyzed · 1 company · Latest 2025-11-13

Companies

Company Buys Sells Direction
Mineralys Therapeutics, Inc. MLYS 0 17 Net selling

Activity

November 2025
high
Sell
119,524 shares
$5,363,716
Significance 7/10

CFO Adam Scott sold 119,524 shares at blended avg $44.88 on 2025-11-11, reducing stake by 86.0% to 19.4K shares; stock now at $44.29 vs 52-week high $47.33.

CFO Adam Scott executed 9 separate sales totaling 119,524 shares for $5,363,715.88 in a single day, reducing his holdings from 138.9K shares to 19.4K shares (an 86.0% reduction). The transaction occurred near the company's 52-week high ($47.33), with the blended average price of $44.88 only 6.4% below peak. Mineralys remains fundamentally unprofitable with $-36,932,000.00 net income over the most recent full fiscal year; the large, concentrated liquidation by the CFO—the executive responsible for financial reporting and corporate governance—warrants investor scrutiny of whether material financial or operational concerns informed the timing. The historical pattern at MLYS shows poor 90-day sell timing (1 of 5 prior sells well-timed), and the dramatic reduction in his personal stake creates a gap between insider ownership and public expectations of board confidence in the turnaround narrative.

July 2025
high
Sell
73,678 shares
$1,077,477
Significance 6/10

CFO Adam Scott sells 73,678 shares for $1,077,476.77 across 4 transactions; reduces stake 35.7% amid unprofitable operations.

Adam Scott, CFO and Secretary, executed 4 separate sales totaling 73,678 shares (73.7K shares) for $1,077,476.77 over three trading days (July 28–30, 2025) at prices ranging from $14.00 to $15.10. This sale reduces his holdings from 206,612 shares (206.6K shares) to 132,934 shares (132.9K shares), a 35.7% reduction in pre-transaction holdings. The sales occurred near the stock's 52-week high (current price $14.49 is -14.1% from the $16.87 high), and the company reported a net loss of $-42,211,000.00 ($-42.2M) in its most recent full fiscal year. His single prior sale at MLYS (June 2024) achieved a 90-day well-timed outcome (stock fell afterward), and his cross-ticker track record shows a 100.00% well-timed rate on sells; however, this prior data point at the same ticker represents only 1 historical observation and cannot be relied upon as a predictive signal for this filing.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access